Chronic Kidney Disease Market

Market Overview: 

The 7 major chronic kidney disease markets reached a value of US$ 5.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 11.0 Billion by 2034, exhibiting a growth rate (CAGR) of 8.27% during 2024-2034.

The chronic kidney disease market has been comprehensively analyzed in IMARC's new report titled "Chronic Kidney Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chronic kidney disease is a medical condition in which progressive damage and gradual loss of renal function occur over time. This can result in the buildup of excess fluid, electrolytes, and waste from the blood in the body, causing severe health problems. The disease exhibits mild to no symptoms in the early stages, but over time people may experience nausea, loss of appetite, vomiting, fatigue, weakness, muscle cramps, shortness of breath, dry and itchy skin, swelling of feet and ankles, etc. The other common indications of this ailment include sleep problems, unexplained weight loss, decreased mental sharpness, chest pain, high blood pressure, water-electrolyte imbalance, abnormal heart rhythm, failure to thrive, insufficient urine production, etc. Diagnosing the condition usually requires a review of the patient's symptoms and medical history, along with a physical and neurological exam. The healthcare provider may perform several investigations, such as blood workups, imaging studies, urine tests, etc., to determine the severity of the disease. Additionally, a kidney biopsy is recommended, which involves removing a sample of renal tissue and examining it under a microscope.

The increasing cases of high blood pressure and diabetes, which can exert strain on the renal blood vessels and cause damage, are primarily driving the chronic kidney disease market. In addition to this, the rising incidence of renal stones, enlarged prostate, and some cancer that result in prolonged obstruction of the urinary tract are also bolstering the market growth. Furthermore, the inflating utilization of effective drugs, including diuretics, angiotensin-converting enzyme (ACE) inhibitors, statins, etc., to treat the underlying symptoms and slow the progression of the illness is acting as another significant growth-inducing factor. Apart from this, the escalating application of peritoneal dialysis therapy, which uses the lining of the abdominal cavity to remove waste and excess fluids from the body, is further creating a positive outlook for the market. Additionally, the emerging popularity of sodium-glucose co-transporter 2 (SGLT2) inhibitors, such as empagliflozin and canagliflozin, for treating this condition since they can reduce albuminuria and enhance renal outcomes is expected to drive the chronic kidney disease market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the chronic kidney disease market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for chronic kidney disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic kidney disease market in any manner.

Recent Developments:

• In March 2024, Bayer Healthcare, in collaboration with LASCO Pharmaceutical Division, has launched finerenone, a ground-breaking medicine marketed as Firialta, for the treatment of chronic kidney disease.
• In November 2023, Boehringer Ingelheim reported excellent 14-week Phase II data for BI 690517, a new selective aldosterone synthase inhibitor (ASi) for the treatment of chronic kidney disease. When BI 690517 was used with empagliflozin, an SGLT2 inhibitor, the results showed a significant reduction in albuminuria, a marker of kidney damage, of up to 39.5% compared to placebo.
• In September 2023, Boehringer Ingelheim and Eli Lilly and Company announced that the U.S. FDA had approved Jardiance (empagliflozin) 10 mg tablets to reduce the likelihood of a sustained decline in estimated glomerular filtration rate, end-stage kidney disease, cardiovascular death and hospitalization in adult individuals with chronic kidney disease at risk of progression.

Key Highlights:

• Chronic renal disease is a progressive illness that affects more than 10% of people worldwide, or over 800 million people.
• More than 35 million persons in the United States are affected by chronic kidney disease.
• Kidney disease is more frequent in women (14% vs. men (12%).
• Chronic kidney disease is more common in the elderly population. Nearly half of individuals with chronic kidney disease are above the age of 70.
• In population-based research, diabetic nephropathy is the leading cause of chronic kidney disease.

Drugs:

Farxiga (dapagliflozin) refers to a first-in-class, oral, once-daily sodium-glucose cotransporter 2 (SGLT2) inhibitor. It has been approved in the United States to minimize the risk of persistent estimated glomerular filtration rate decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in individuals with chronic kidney disease at risk of progression.

US-APR2020 is a natural probiotic formulation that metabolizes nitrogenous waste, which typically diffuses from the bloodstream to the gut. When these waste products build up in high concentrations in the blood, they become highly toxic and can cause severe harm to numerous organ systems if not effectively eliminated. The US-APR2020 uses nitrogenous wastes as nutrition to effectively maintain healthy kidney function.

ALLN-346 is a first-in-class, non-absorbed, orally given enzyme being developed to treat hyperuricemia and gout in advanced chronic kidney disease. ALLN-346 is a bio-engineered enzyme that degrades urate in the gastrointestinal tract without systemic absorption, lowering systemic urate levels in individuals with hyperuricemia, gout, or chronic renal disease.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the chronic kidney disease market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the chronic kidney disease market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current chronic kidney disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the chronic kidney disease market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the chronic kidney disease market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the chronic kidney disease market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of chronic kidney disease across the seven major markets?
• What is the number of prevalent cases (2018-2034) of chronic kidney disease by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of chronic kidney disease by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with chronic kidney disease across the seven major markets?
• What is the size of the chronic kidney disease patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of chronic kidney disease?
• What will be the growth rate of patients across the seven major markets?
   

Chronic Kidney Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for chronic kidney disease drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic kidney disease market?
• What are the key regulatory events related to the chronic kidney disease market?
• What is the structure of clinical trial landscape by status related to the chronic kidney disease market?
• What is the structure of clinical trial landscape by phase related to the chronic kidney disease market?
• What is the structure of clinical trial landscape by route of administration related to the chronic kidney disease market?